A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection

Journal of Hepatology

Volumn 61, Issue 6, 2014, Pages 1238-1246

  Muir, Andrew J ^a   Arora, Sanjeev ^b   Everson, Gregory ^c   Flisiak, Robert ^d   George, Jacob ^e   Ghalib, Reem ^f   Gordon, Stuart C ^g   Gray, Todd ^h   Greenbloom, Susan ⁱ   Hassanein, Tarek ^j   Hillson, Jan ^h   Horga, Maria Arantxa ^h   Jacobson, Ira M ^k   Jeffers, Lennox ^l   Kowdley, Kris V ^m   Lawitz, Eric ⁿ   Lueth, Stefan ^o   Rodriguez Torres, Maribel ^p   Rustgi, Vinod ^q   Shemanski, Lynn ^h   Shiffman, Mitchell L ^r   Srinivasan, Subasree ^h   Vargas, Hugo E ^s   Vierling, John M ^t   Xu, Dong ^h   Lopez Talavera, Juan C ^h   Zeuzem, Stefan ^u   more..

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Texas Clinical Research Institute   (United States)

^g HENRY FORD HOSPITAL   (United States)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ Toronto Digestive Disease Associates Inc   (Canada)

^j SCTI Research Foundation   (United States)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m VIRGINIA MASON MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^o UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^p Fundacion de Investigacion   (Puerto Rico)

^q Metropolitan Research   (United States)

^r Liver Institute of Virginia   (United States)

^s MAYO CLINIC   (United States)

^t BAYLOR COLLEGE OF MEDICINE   (United States)

^u UNIVERSITY HOSPITAL FRANKFURT   (Germany)

more..

Author keywords

Efficacy; Safety; SVR; Treatment naive; Type III interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON LAMBDA; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; INTERFERON; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHILL; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERONS; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84922813934     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.07.022     Document Type: Article

References (43)

1. Vertex Pharmaceuticals I. INCIVEK™ (telaprevir) Prescribing Information; 2012.
2. Merck Sharp & Dohme Corp. VICTRELISTM (boceprevir) [package insert]; 2013.
3. Janssen Therapeutics. OLYSIO™ (simeprevir) Prescribing Information; 2014.
4. Food and Drug Administration. SOVALDI™ (sofosbuvir) Prescribing Information; 2014.
5. J.R. Kramer, F. Kanwal, P. Richardson, M. Mei, and H.B. El-Serag Gaps in the achievement of effectiveness of HCV treatment in national VA practice J Hepatol 56 2012 320 325
6. C.E. McGowan, A. Monis, B.R. Bacon, J. Mallolas, F.L. Goncales, and I. Goulis A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care Hepatology 57 2013 1325 1332
7. J.G. McHutchison, M. Manns, K. Patel, T. Poynard, K.L. Lindsay, and C. Trepo Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
8. M.G. Ghany, D.B. Strader, D.L. Thomas, L.B. Seeff American Association for the Study of Liver Diseases Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
9. K.R. Reddy, D.R. Nelson, and S. Zeuzem Ribavirin: current role in the optimal clinical management of chronic hepatitis C J Hepatol 50 2009 402 411
10. L.C. Platanias, and E.N. Fish Signaling pathways activated by interferons Exp Hematol 27 1999 1583 1592
11. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
12. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
13. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
14. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
15. P. Sheppard, W. Kindsvogel, W. Xu, K. Henderson, S. Schlutsmeyer, and T.E. Whitmore IL-28, IL-29 and their class II cytokine receptor IL-28R Nat Immunol 4 2003 63 68
16. S.V. Kotenko, G. Gallagher, V.V. Baurin, A. Lewis-Antes, M. Shen, and N.K. Shah IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex Nat Immunol 4 2003 69 77
17. L. Dumoutier, A. Tounsi, T. Michiels, C. Sommereyns, S.V. Kotenko, and J.C. Renauld Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling J Biol Chem 279 2004 32269 32274
18. Z. Zhou, O.J. Hamming, N. Ank, S.R. Paludan, A.L. Nielsen, and R. Hartmann Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases J Virol 81 2007 7749 7758
19. N. Ank, H. West, C. Bartholdy, K. Eriksson, A.R. Thomsen, and S.R. Paludan Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo J Virol 80 2006 4501 4509
20. S.E. Doyle, H. Schreckhise, K. Khuu-Duong, K. Henderson, R. Rosler, and H. Storey Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes Hepatology 44 2006 896 906
21. Z. Yin, J. Dai, J. Deng, F. Sheikh, M. Natalia, and T. Shih Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells J Immunol 189 2012 2735 2745
22. A.J. Muir, M.L. Shiffman, A. Zaman, B. Yoffe, A. de la Torre, and S. Flamm Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection Hepatology 52 2010 822 832
23. Food and Drug Administration. Copegus™ (ribavirin) label 2010; 2010: < http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021511s020lbl.pdf >.
24. Food and Drug Administration. PEGASYS (peginterferon alfa-2a) label 2002; 2012.
25. T. Marcello, A. Grakoui, G. Barba-Spaeth, E.S. Machlin, S.V. Kotenko, and M.R. MacDonald Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics Gastroenterology 131 2006 1887 1898
26. S.G. Maher, F. Sheikh, A.J. Scarzello, A.L. Romero-Weaver, D.P. Baker, and R.P. Donnelly IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity Cancer Biol Ther 7 2008 1109 1115
27. V. Francois-Newton, G. Magno de Freitas Almeida, B. Payelle-Brogard, D. Monneron, L. Pichard-Garcia, and J. Piehler USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response PLoS One 6 2011 e22200
28. J.M. Vierling, M. Lataillade, E. Gane, S. Lueth, L. Serfaty, and G. Taliani Sustained virologic response (SVR12) in HCV genotype 1 patients receiving peginterferon lambda in combination with ribavirin and either daclatasvir or asunaprevir: interim results from the D-LITE study Hepatol Int 7 2013 S438
29. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, and J. McCone Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
30. A. Andriulli, A. Mangia, A. Iacobellis, A. Ippolito, G. Leandro, and S. Zeuzem Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis Aliment Pharmacol Ther 28 2008 397 404
31. A.J. Thompson, A.J. Muir, M.S. Sulkowski, D. Ge, J. Fellay, and K.V. Shianna Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 2010 120 129
32. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, and N. Sakamoto Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
33. C.M. Lange, and S. Zeuzem IL28B single nucleotide polymorphisms in the treatment of hepatitis C J Hepatol 55 2011 692 701
34. S. Zeuzem, R. Hultcrantz, M. Bourliere, T. Goeser, P. Marcellin, and J. Sanchez-Tapias Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3 J Hepatol 40 2004 993 999
35. P. Marcellin, H. Cheinquer, M. Curescu, G.M. Dusheiko, P. Ferenci, and A. Horban High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials Hepatology 56 2012 2039 2050
36. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
37. L. De Franceschi, G. Fattovich, F. Turrini, K. Ayi, C. Brugnara, and F. Manzato Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage Hepatology 31 2000 997 1004
38. G. Everson, T. Gray, J.L. Hillson, A. Horga, D. Xu, and D. Fontana Pegylated interferon lambda ameliorates ribavirin (RBV)-induced anemia in HCV patients by maintaining compensatory erythropoiesis: analysis of EMERGE phase 2b results through week 12 [Abstract] Hepatology 54 2011 993A 994A
39. K.R. Reddy, M.L. Shiffman, T.R. Morgan, S. Zeuzem, S. Hadziyannis, and F.M. Hamzeh Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment Clin Gastroenterol Hepatol 5 2007 124 129
40. F. Poordad, E. Lawitz, K.R. Reddy, N.H. Afdhal, C. Hezode, and S. Zeuzem Effects of ribavirin dose reduction vs. erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection - A randomized trial Gastroenterology 145 2013 e5
41. K. Ishak, A. Baptista, L. Bianchi, F. Callea, J. De Groote, and F. Gudat Histological grading and staging of chronic hepatitis J Hepatol 22 1995 696 699
42. P. Bedossa, and T. Poynard An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology 24 1996 289 293
43. Y. Ngo, M. Munteanu, D. Messous, F. Charlotte, F. Imbert-Bismut, and D. Thabut A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C Clin Chem 52 2006 1887 1896